Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2007 1
2008 5
2009 1
2010 3
2011 7
2012 4
2013 4
2014 10
2015 7
2016 6
2017 3
2018 7
2019 6
2020 8
2021 12
2022 4
2023 9
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Hypercalcemia of Malignancy.
Hu MI. Hu MI. Endocrinol Metab Clin North Am. 2021 Dec;50(4):721-728. doi: 10.1016/j.ecl.2021.07.003. Endocrinol Metab Clin North Am. 2021. PMID: 34774243 Review.
Hypercalcemia and cancer: Differential diagnosis and treatment.
Zagzag J, Hu MI, Fisher SB, Perrier ND. Zagzag J, et al. Among authors: hu mi. CA Cancer J Clin. 2018 Sep;68(5):377-386. doi: 10.3322/caac.21489. Epub 2018 Sep 21. CA Cancer J Clin. 2018. PMID: 30240520 Free article. Review.
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. Among authors: hu mi. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
Denosumab for treatment of hypercalcemia of malignancy.
Hu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK. Hu MI, et al. J Clin Endocrinol Metab. 2014 Sep;99(9):3144-52. doi: 10.1210/jc.2014-1001. Epub 2014 Jun 10. J Clin Endocrinol Metab. 2014. PMID: 24915117 Free PMC article. Clinical Trial.
CDC73-Related Disorders.
Skefos CM, Waguespack SG, Perrier ND, Hu MI. Skefos CM, et al. Among authors: hu mi. 2008 Dec 31 [updated 2023 Sep 21]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2008 Dec 31 [updated 2023 Sep 21]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301744 Free Books & Documents. Review.
Medullary thyroid carcinoma.
Jaber T, Dadu R, Hu MI. Jaber T, et al. Among authors: hu mi. Curr Opin Endocrinol Diabetes Obes. 2021 Oct 1;28(5):540-546. doi: 10.1097/MED.0000000000000662. Curr Opin Endocrinol Diabetes Obes. 2021. PMID: 34292174 Review.
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Subbiah V, et al. Among authors: hu mi. Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501. doi: 10.1016/S2213-8587(21)00120-0. Epub 2021 Jun 9. Lancet Diabetes Endocrinol. 2021. PMID: 34118198 Clinical Trial.
93 results